Vosoritide, a precision pharmacological treatment, was approved for use in patients with achondroplasia in 2021. This Consensus Statement brings together an international group of experts to provide guidelines on the use of vosoritide.
- Ravi Savarirayan
- Julie Hoover-Fong
- Svein Otto Fredwall
